133 related articles for article (PubMed ID: 16232205)
1. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Yamada Y; Yamamoto N; Shimoyama T; Horiike A; Fujisaka Y; Takayama K; Sakamoto T; Nishioka Y; Yasuda S; Tamura T
Cancer Sci; 2005 Oct; 96(10):721-8. PubMed ID: 16232205
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
Punt CJ; Fumoleau P; van de Walle B; Faber MN; Ravic M; Campone M
Ann Oncol; 2001 Sep; 12(9):1289-93. PubMed ID: 11697842
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C; Zanetta S; Roché H; Schellens JH; Faber MN; Wanders J; Ravic M; Droz JP;
Eur J Cancer; 2003 May; 39(8):1097-104. PubMed ID: 12736109
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E; ten Bokkel Huinink WW; Taïeb J; Beijnen JH; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand JP; Schellens JH;
J Clin Oncol; 2002 Aug; 20(16):3508-21. PubMed ID: 12177112
[TBL] [Abstract][Full Text] [Related]
6. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS; Huitema AD; Copalu W; Yamada Y; Tamura T; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 May; 13(10):2970-6. PubMed ID: 17504998
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
11. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
van den Bongard HJ; Sparidans RW; Critchley DJ; Beijnen JH; Schellens JH
Invest New Drugs; 2004 Apr; 22(2):151-8. PubMed ID: 14739663
[TBL] [Abstract][Full Text] [Related]
13. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
[TBL] [Abstract][Full Text] [Related]
15. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
van sen Bongard HJ; Pluim D; Rosing H; Nan-Offeringa L; Schot M; Ravic M; Schellens JH; Beijnen JH
Anticancer Drugs; 2002 Sep; 13(8):807-14. PubMed ID: 12394264
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
Dittrich C; Zandvliet AS; Gneist M; Huitema AD; King AA; Wanders J
Br J Cancer; 2007 Feb; 96(4):559-66. PubMed ID: 17285128
[TBL] [Abstract][Full Text] [Related]
17. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
Haddad RI; Weinstein LJ; Wieczorek TJ; Bhattacharya N; Raftopoulos H; Oster MW; Zhang X; Latham VM; Costello R; Faucher J; DeRosa C; Yule M; Miller LP; Loda M; Posner MR; Shapiro GI
Clin Cancer Res; 2004 Jul; 10(14):4680-7. PubMed ID: 15269140
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
Zhang Y; Si D; Chen X; Lin N; Guo Y; Zhou H; Zhong D
Br J Clin Pharmacol; 2007 Jul; 64(1):67-74. PubMed ID: 17298483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
